TSLA
Tesla
-- 385.846 NVDA
NVIDIA
-- 137.434 RGTI
Rigetti Computing
-- 16.1175 PLTR
Palantir
-- 75.545 MSTR
MicroStrategy
-- 302.170 
Merger postponed
$Aditxt (ADTX.US)$ New date is January 31. Ugh.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
韭菜幼苗 : no wonder today no volume
algerlow : may i know where you get your updates or news from?
TheOracleOfBroMaha : So McSnackers… In most mergers the stock price generally levels off like a glass of water at the spot where it’s gonna be when the merger takes place. The price of the stock continues to go down. I don’t have any issue with the company. I think they’re an OK company obviously on the verge of becoming listed, but it won’t happen since they’re also on the verge of being merged. I think it’s interesting that the stock price continues to sync. Talk to text ha ha. But if you really believe that the price will go up to a dollar or somewhere like that at the merger I mean, aren’t you buying them all you can I’m I know it may not that may not be the case but I guess I’m trying to ask what’s the your basis in the calculation or your guess and if it’s just a guess that’s cool not guess… fml
Anywhoooo I follow u & LOVE your advice- no promises of course! But well let’s say you have $5k to “play with” … (side money, won’t cry if u lost it…) Would you set it here!? Do you really believe there’s a decent chance the price could hit 1….? I’m in for a small stack of “no cry” at about .19…. Are there little chance of a delist & a v good chance of a merger? I’d love if you’d elaborate please?
TheOracleOfBroMaha : Well this may be long- I asked a.i. about the merger and here is some info- (note also asked re specifics on merger which I’ll add under if possible- it’s a lot but good!
Aditxt, Inc. (NASDAQ: ADTX) is in the process of acquiring Evofem Biosciences, Inc. (OTCQB: EVFM), a women’s health innovator known for products like Phexxi®, a non-hormonal contraceptive gel. 
Merger Details:
• Structure: Aditxt’s subsidiary, Adifem, Inc., will merge with and into Evofem, resulting in Evofem becoming a wholly-owned subsidiary of Aditxt. 
• Investments: Aditxt has made several equity investments in Evofem, including a $2.28 million purchase of Evofem Series F-1 convertible preferred stock, marking the final investment stipulated under the Amended and Restated Merger Agreement. 
• Timeline: The merger agreement’s end date has been extended to January 2025 to allow additional time for completion. 
Market and Press Reactions:
• Stock Performance: Both companies have experienced stock volatility, common in merger situations.
• Press Coverage: The merger has been covered by financial news outlets, highlighting the strategic fit and potential synergies. 
Considerations for Investors:
• Due Diligence: Review official filings, press releases, and financial statements of both companies.
• Market Sentiment: Monitor financial news and analysis for insights into market perceptions.
• Professional Advice: Consult a financial advisor to assess how this merger aligns with your investment goals and risk tolerance.
If you have specific questions or need further details on any aspect of this merger, feel free to ask!
TheOracleOfBroMaha : So here are the actual details of the murder itself and artificial intelligence information on that for us… will be 2 parts (too long)
This situation involves several important factors, including the merger itself and the warrants issued by Aditxt, Inc. Here’s a breakdown of the details you provided:
Key Points from the Merger and Warrants Details:
1. Warrant Exercise Price and Terms:
• The warrants allow holders to purchase common stock at $1.582 per share.
• These warrants become exercisable 6 months and 1 day after issuance and expire 5 years after issuance.
• If no registration statement is effective, holders can opt for a cashless exercise, meaning they receive shares instead of paying cash.
2. Adjustments and Provisions:
• Stock Splits and Dividends: If there’s a stock split or dividend, the exercise price and number of shares are adjusted accordingly.
• Anti-Dilution Provisions: If new shares are issued at a lower price, the exercise price of these warrants may be lowered (down to a floor price of $0.295, subject to shareholder approval).
3. Ownership Limits:
• The warrants have a 4.99% ownership limitation, meaning a holder cannot own more than 4.99% of the company. This limit can be increased to 9.99% if the holder chooses.
4. Fundamental Transactions:
• If a major corporate event (e.g., merger) occurs, warrant holders can:
•
TheOracleOfBroMaha : P 2
Exercise the warrants for shares in the successor entity, or
• Demand a cash payout based on the Black-Scholes value of the warrants.
5. Share Reservation:
• The company must reserve enough shares (initially 200% of the total warrant shares) to ensure all warrants can be exercised.
What This Means for You as a Potential Investor:
1. Buying at $0.18 Per Share:
• If you’re buying the common stock at $0.18 per share, you’re not directly purchasing these warrants. However, the warrants might affect the stock price.
• Warrants can lead to dilution when exercised, as new shares are issued, potentially lowering the value of existing shares.
2. Merger Impact:
• The merger (scheduled for January 31) could cause significant price movement. If the market views the merger as beneficial, the stock price may rise. If there are concerns or uncertainties, the price could fall.
• Mergers often introduce volatility, as investors speculate on the combined company’s future performance.
3. Risks of Dilution:
• The warrants have anti-dilution provisions, meaning more shares could be issued at lower prices in certain situations. This would reduce the value of your $0.18 shares.
• A high number of warrants being exercised could increase the share supply, further pressuring the price.
4. Ownership Limits and Control:
• The ownership cap (4.99% or 9.99%) might limit any single entity’s influence but could also signal that the company is protecting itself from over-consolidation.
5. Warrant Floor Price:
• A floor price of $0.295 indicates the company cannot issue shares below this level without shareholder approval. This could provide some support for the stock price, but it’s not guaranteed.
TheOracleOfBroMaha : Part 3
Key Risks:
1. Uncertainty Around the Merger:
• Mergers can fail, be delayed, or result in unfavorable terms.
• If the merger is seen as unfavorable, the stock could drop below $0.18.
2. Dilution from Warrants:
• The exercise of warrants, particularly at a lower price, could dilute the stock and pressure its value.
3. Speculative Nature:
• Stocks trading at very low prices (e.g., $0.18) are often speculative and volatile, making them risky investments.
4. Timing and Execution:
• The merger’s success, terms, and timeline could influence short-term and long-term stock performance.
Potential Rewards:
1. If the merger is successful and viewed positively, the stock price could rise, creating an opportunity for significant gains.
2. At $0.18 per share, the stock is relatively inexpensive, which means a small increase in price could yield a high percentage return.
Conclusion and Advice:
• This investment carries significant risk due to the speculative nature of the stock, the uncertainty around the merger, and the potential for dilution from the warrants.
• If you believe in the company’s potential and the merger’s success, buying at $0.18 could offer upside. However, it’s essential to approach this as a high-risk, high-reward investment.
TheOracleOfBroMaha : Mick snacks- I want to apologize for loading all this stuff up under your comment section. I hope I’m not Mc-boring you
B T W I answered my own question when I was the ones I was asking you from looking up that information and here’s my answer if I had that $5000 that I wouldn’t cry over losing… I would spend 1000 of it at $.19 a share right now and put 4000 somewhere else. So I’m not very confident just my opinion that this is going to surge by any means before or on January 31 or even after. I hope it is I think it’s a good company and it sounds like it deserves to, but its earnings have been extraordinarily poor however I think the CEO if he’s being honest knows what we don’t which is that their earnings are gonna explode. He’s obviously spending money that he thinks he has so I guess we’ll find out. I’m willing to be 1000 and see if it turns into five but I’d rather spend the other four on beer and lewd women
Mcsnacks H Tupack OP TheOracleOfBroMaha : The other 2 companies are being delisted which would mean that capital would need to be integrated into this company. The investors from the other companies shares were Reverse split to make them equal 1.00. They also have FDA approval coming so this merger will bring a multitude of news announcements driving the price. But this is based on the merger being successful which has already encountered a snag with the debt being paid off. This caused a delay. Now the company must keep themselves from being delisted when they meet with the SEC on Monday. This is why buying up shares became too risky when they announced a postponement in the merger. At least until there can be an announcement for an extension until January 31. Evofem still requires a vote in order to merge.
TheOracleOfBroMaha : Thank you so much for that information. I think I’ll keep the shares I have. I did not know what you just told me so that’s really interesting information and stuff that ChatGPT failed to tell me I will reprimand my chat but immediately. Thank you, snacks you’re always spot on I appreciate you.
View more comments...